Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Catapult

“Brexit has been a catalyst for UK clinical research… it’s turbocharged change”

The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?

- PMLiVE

Vertex chief Jeffrey Leiden to weigh in on Orkambi inquiry

Will be joined by chief commercial officer Stuart Arbuckle

Gene Genie

Evolution will find new markets for gene and cell therapies

- PMLiVE

UK launches National Genomic Healthcare strategy

New initiative unveiled to coincide with Rare Disease Day

- PMLiVE

Roche buys gene therapy specialist Spark for $4.3bn

Can compete with rival Novartis in fast-developing area

- PMLiVE

BioMarin prepares for haemophilia A gene therapy data readout, filing

Key long-term data expected in July

- PMLiVE

Cell therapy disruptor Mogrify gains $3.7m in funding and a new leader

Former Horizon chief Darrin Disley to lead the company through series A round

Cell and gene therapy

Tackling the manufacturing cost and complexity challenges

- PMLiVE

UCB signs research deal with King’s College London

Company and academic researchers to share one facility

- PMLiVE

Bicycle Therapeutics to tackle AMR with government funding

Biotech to discover new class of antibacterial agents

Pharma iPad detailing doctors physicians

A genomics and digital-led NHS is possible – but investment in staff essential

Powerful technologies will lead to an “evolution of the patient-doctor relationship”

- PMLiVE

Industry concerned about ‘rushed’ Brexit withdrawal legislation

The Patents Amendment could weaken the UK’s IP framework, warns biopharma

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links